Multimodality cisplatin treatment in non
โ
Barry Epstein; Peter K. Leichner; Stanley E. Order; David Ettinger
๐
Article
๐
1991
๐
John Wiley and Sons
๐
English
โ 520 KB
Twenty-eight patients with alpha-fetoprotein-positive (AFP+) nonresectable hepatoma have been enrolled in a new multimodality Phase I, II program. Induction therapy consisted of 50 mg/m2 intravenous cisplatin followed by 2100 cGy irradiation to the tumor volume in seven fractions over 10 days. Hepat